LRG1 Canine

Leucine-Rich Alpha-2-Glycoprotein 1 (LRG1) is a protein that belongs to the leucine-rich repeat (LRR) family. This family of proteins is known for its role in protein-protein interactions, signal transduction, and cell adhesion and development . LRG1 has been studied extensively in humans and other species, including canines, due to its involvement in various physiological and pathological processes.

LRG1 is a 312 amino acid protein that contains eight leucine-rich repeats (LRR), four N-linked glycosylation sites, one O-linked glycosylation site, and two disulfide bonds . Upon cleavage of the N-terminal signal peptide, LRG1 is released into the extracellular space. The mature form of LRG1, which is approximately 50 kDa, may vary in weight depending on the glycosylation pattern and multimer formation .

In canines, LRG1 is involved in several key physiological processes. It is expressed during granulocyte differentiation and has been shown to play a role in promoting neovascularization (new blood vessel growth) by influencing transforming growth factor-beta (TGF-β) signaling in endothelial cells . This makes LRG1 a crucial player in wound healing and tissue repair.

LRG1 has been implicated in the pathogenesis of numerous diseases, including cancer, eye disease, neurodegenerative diseases, diabetes, lung, and kidney diseases . In canines, elevated levels of LRG1 have been associated with inflammatory conditions and certain types of cancer. For instance, LRG1 levels are markedly elevated in acute appendicitis and could potentially be used as a diagnostic aid .

Given its role in disease pathogenesis, LRG1 is being explored as a potential therapeutic target. Inhibition of LRG1 has been shown to normalize tumor vasculature, improve the efficacy of cytotoxic and immune therapies, and restrict metastatic spread . This makes LRG1 a promising target for the development of new treatments for various diseases in canines.